해부 병리학 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Anatomic Pathology Market Size, Share & Trends Analysis Report By Product & Service (Instruments, Consumables, Services), By Application (Disease Diagnosis, Drug Discovery And Development), By End Use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,710,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,174,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,102,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

해부 병리학 시장 : 개요

세계의 해부 병리학 시장 규모는 2024년에 347억 2,000만 달러로 추정되며, 2033년까지 807억 8,000만 달러에 달할 것으로 예측됩니다.

2025년부터 2033년까지 9.79%의 CAGR을 기록할 것으로 예상됩니다. 시장 성장을 견인하는 주요 요인으로는 전 세계 암 및 만성질환 부담 증가, 정밀의료 및 맞춤형 의료의 보급 확대, 디지털 병리 및 인공지능(AI) 기술 발전 등을 꼽을 수 있습니다.

예를 들어, 2025년 7월 PathAI(미국)는 자사의 AISight 1 영상관리 시스템(IMS)을 탑재한 세계 최초의 디지털 해부병리 연구소 네트워크 'Precision Pathology Network(PPN)'를 출범했습니다. PPN은 PathAI가 바이오제약 업계와 협력하여 개발한 최신 AI 탑재 병리 솔루션에 대한 조기 접근을 제공하고, 참여 검사기관이 실제 임상 병리 데이터를 수익화할 수 있도록 하며, 바이오제약 기업이 지원하는 근거 창출 연구를 지원하고, AI 병리를 활용한 새로운 임상 개발 전략을 가능하게 하는 것을 목표로 합니다. AI 병리를 활용한 새로운 임상 개발 전략을 가능하게 하는 것을 목표로 하고 있습니다. 또한, 고령화와 헬스케어의 증가는 전 세계 해부 병리학 산업의 성장을 촉진하고 있습니다. '세계 인구 예측 2024'에 따르면, 세계 인구는 향후 50-60년 동안 계속 증가하여 2024년 82억 명에서 2080년대 중반에는 약 103억 명으로 정점을 찍을 것으로 예상됩니다.

분자 병리학 및 동반진단(CDx)의 발전은 질병 진단 및 치료에 있어 보다 정밀하고 개별화된 표적 치료를 가능하게 하여 세계 시장을 크게 확대시키고 있습니다. 분자병리학은 특히 암을 비롯한 특정 질환과 관련된 유전적, 분자적, 세포적 변화를 감지하여 보다 빠르고 정확한 진단을 가능하게 합니다. 동반진단은 특정 치료법의 혜택을 가장 많이 받을 가능성이 가장 높은 환자를 식별하여 표적 치료제 사용을 유도하는 역할을 합니다. 이러한 진단과 치료의 결합은 종양학을 비롯한 의료 분야에서 점점 더 많이 활용되고 있으며, 고급 병리 서비스에 대한 수요를 견인하고 있습니다. 제약사들이 맞춤의료에 대한 투자를 지속하고 규제 당국이 CDx를 의약품 개발 프로세스에 통합하는 것을 장려하는 가운데, 해부 병리학의 역할은 전통적인 조직학을 넘어 분자 수준의 지식을 포함하는 방향으로 확대되고 있으며, 이는 시장의 성장과 혁신을 가속화하고 있습니다.

질병 부담의 증가와 기술 발전 외에도 세계 해부 병리학 산업을 이끄는 요인은 여러 가지가 있습니다. 조기 및 정확한 진단의 중요성에 대한 환자와 의료진의 인식과 교육이 향상되면서 병리 진단 서비스에 대한 수요가 확대되고 있습니다. 정기적인 건강검진 및 예방 의료 프로그램을 통한 생검 시술의 증가는 병리학적 분석에 대한 수요를 증가시키고 있습니다. 또한, 병원 중심의 의료에서 외래 진료 및 전문 진단 센터로의 전환은 병리 진단 서비스의 접근성과 효율성을 향상시키고 있습니다. 선진국의 유리한 상환 정책과 더불어 신흥국의 진단 인프라 강화를 위한 정부 지원책도 시장 성장을 더욱 촉진하고 있습니다.

또한, 진단 검사 기관, 병원, 기술 기업 간의 전략적 제휴, 합병, 인수합병은 혁신을 촉진하고 지역 간 서비스 제공의 확장을 촉진하고 있습니다.

목차

제1장 해부 병리학 시장 : 조사 방법과 범위

제2장 해부 병리학 시장 : 주요 요약

• 시장 개요
• 제품 및 서비스 개요
• 용도 개요
• 최종 용도 개요
• 경쟁 구도 개요

제3장 해부 병리학 시장 : 변수, 동향, 범위

• 시장 구분·범위
• 시장 연관 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
• 시장 성장 촉진요인 분석
  • 세계의 암·만성질환 부담 증가
  • 정밀의료·맞춤형 의료의 도입 확대
  • 디지털 병리학이나 인공지능(AI)의 진보
  • 분자 병리학이나 동반진단(CDx) 확대
  • 고령화와 의료 확대
• 시장 성장 억제요인 분석
  • 첨단 진단 기기의 고비용
  • 엄격한 규제 및 컴플라이언스 요건
  • 데이터 프라이버시와 사이버 보안 문제
• Porter's Five Forces 분석
• PESTLE 분석
• 파이프라인 분석

제4장 해부 병리학 시장 : 제품 및 서비스별 추정·동향 분석

• 해부 병리학 시장 : 변동 분석, 제품 및 서비스별
• 제품
  • 기기
  • 소모품
  • 서비스

제5장 해부 병리학 시장 : 용도별 추정·동향 분석

• 해부 병리학 시장 : 변동 분석, 용도별
• 질환 진단
• Drug Discovery & Development
• 기타

제6장 해부 병리학 시장 : 최종 용도별 추정·동향 분석

• 해부 병리학 시장 : 변동 분석, 최종 용도별
• 병원
• 진단 검사실
• 연구기관
• 기타

제7장 해부 병리학 시장 : 지역별 사업 분석

• 시장 개요 : 지역별
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제8장 경쟁 구도

• 기업 분류
• 전략 매핑
  • 신제품 발매
  • 사업 제휴
  • 기업 인수
  • 합작투자
  • 자금 조달
• 주요 기업의 시장 점유율 분석(2024년)
• 기업 히트맵 분석
• 기업 개요
  • Danaher
  • PHC Holdings Corporation
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings
  • F. Hoffmann-La Roche AG
  • Agilent Technologies, Inc.
  • Sakura Finetek USA, Inc.
  • NeoGenomics Laboratories, Inc.
  • BioGenex
  • Bio SB

KSM

영문 목차

영문목차

Anatomic Pathology Market Summary

The global anatomic pathology market size was estimated at USD 34.72 billion in 2024 and is projected to reach USD 80.78 billion by 2033, growing at a CAGR of 9.79% from 2025 to 2033. Some of the major factors driving the market growth are rising global cancer and chronic disease burden, growing adoption of precision and personalized medicine, and digital pathology and artificial intelligence (AI) advancements.

For instance, in July 2025, PathAI (U.S.) launched the Precision Pathology Network (PPN), a first-of-its-kind network of digital anatomic pathology laboratories powered by PathAI's AISight 1 Image Management System (IMS). The PPN is intended to provide early access to the most recent AI-powered pathology solutions developed by PathAI in collaboration with the biopharma industry, to allow participating laboratories to monetize real-world pathology data, to support biopharma-sponsored evidence generation studies, and to enable novel clinical development strategies that leverage AI-pathology. Furthermore, an aging population and rising healthcare expenditure fuel the growth of the global anatomic pathology industry. As per the World Population Prospects 2024, the world's population is expected to keep growing for another 50 or 60 years, peaking at around 10.3 billion in the mid-2080s, up from 8.2 billion in 2024.

The growth of molecular pathology and companion diagnostics (CDx) is significantly increasing the global market by allowing for more precise, personalized, and targeted approaches to disease diagnosis and treatment. Molecular pathology detects genetic, molecular, and cellular changes associated with specific diseases, most notably cancer, allowing for earlier and more accurate diagnoses. Companion diagnostics help guide the use of targeted therapies by identifying patients who are most likely to benefit from specific treatments. This combination of diagnostics and therapeutics is increasingly being used in oncology and other fields of medicine, driving demand for advanced pathology services. As pharmaceutical companies continue to invest in personalized medicine and regulatory agencies encourage the incorporation of CDx into drug development pipelines, the role of anatomic pathology is expanding beyond traditional histology to include molecular insights, accelerating market growth and innovation.

In addition to rising disease burdens and technological advancements, a number of other factors are driving the global anatomic pathology industry. The growing awareness and education of patients and healthcare providers about the importance of early and accurate diagnosis is driving up demand for pathology services. The growing number of biopsy procedures, driven by routine health screenings and preventive care programs, is increasing the demand for pathology analysis. Furthermore, the transition from hospital-based care to outpatient and specialized diagnostic centers improves pathology services' accessibility and efficiency. Favorable reimbursement policies in developed countries, as well as supportive government initiatives to strengthen diagnostic infrastructure in emerging economies, are further driving market growth.

Furthermore, strategic collaborations, mergers, and acquisitions between diagnostic labs, hospitals, and technology companies are fostering innovation and expanding service offerings across regions.

Global Anatomic Pathology Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the anatomic pathology market report based on product & service, application, end use, and region:

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
  • Microtomes & Cryostat
  • Tissue Processors
  • Automatic Stainers
  • Whole Slide Imaging (WSI) Scanners
  • Other Products
• Consumables
  • Reagents & Antibodies
  • Probes & Kits
  • Others
• Services
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Disease Diagnosis
• Drug Discovery and Development
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Diagnostic Laboratories
• Research Laboratories
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Anatomic Pathology Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Method
    • 1.1.1.2. Application Segment
    • 1.1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Anatomic Pathology Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Product & Service Snapshot
• 2.3. Application Snapshot
• 2.4. End Use Snapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. Anatomic Pathology Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Rising Global Cancer and Chronic Disease Burden
  • 3.4.2. Growing Adoption of Precision and Personalized Medicine
  • 3.4.3. Advancements in Digital Pathology and Artificial Intelligence (AI)
  • 3.4.4. Expansion of Molecular Pathology and Companion Diagnostics (CDx)
  • 3.4.5. Aging Population and Rising Healthcare Expenditure
• 3.5. Market Restraint Analysis
  • 3.5.1. High Cost of Advanced Diagnostic Equipment
  • 3.5.2. Stringent Regulatory and Compliance Requirements
  • 3.5.3. Data Privacy and Cybersecurity Issues
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Anatomic Pathology Market: Product & Service Estimates & Trend Analysis

• 4.1. Anatomic Pathology Market: Test Method Movement Analysis
• 4.2. Products
  • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.2. Instruments
    • 4.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.2.2. Microtomes & Cryostat
      • 4.2.2.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.2.3. Tissue Processors
      • 4.2.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.2.4. Automatic Stainers
      • 4.2.2.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.2.5. Whole Slide Imaging (WSI) Scanners
      • 4.2.2.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.2.6. Other Products
      • 4.2.2.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.3. Consumables
    • 4.2.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.3.2. Reagents & Antibodies
      • 4.2.3.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.3.3. Probes & Kits
      • 4.2.3.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.2.3.4. Others
      • 4.2.3.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.2.4. Services

Chapter 5. Anatomic Pathology Market: Application Estimates & Trend Analysis

• 5.1. Anatomic Pathology Market: Mode Movement Analysis
• 5.2. Disease Diagnosis
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Drug Discovery and Development
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Others
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Anatomic Pathology Market: End Use Estimates & Trend Analysis

• 6.1. Anatomic Pathology Market: Product & Service Movement Analysis
• 6.2. Hospitals
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.3. Diagnostic Laboratories
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Research Laboratories
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Others
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Anatomic Pathology Market: Regional Business Analysis

• 7.1. Regional Market Snapshot
• 7.2. North America
  • 7.2.1. North America Anatomic Pathology Market Estimates and Forecast, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.2.2.2. Key Country Dynamics
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. Reimbursement Scenario
    • 7.2.2.5. Competitive Scenario
  • 7.2.3. Canada
    • 7.2.3.1. Canada Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.2.3.2. Key Country Dynamics
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Reimbursement Scenario
    • 7.2.3.5. Competitive Scenario
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.2.4.2. Key Country Dynamics
    • 7.2.4.3. Regulatory Framework
    • 7.2.4.4. Reimbursement Scenario
    • 7.2.4.5. Competitive Scenario
• 7.3. Europe
  • 7.3.1. Europe Anatomic Pathology Market, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.3.2.2. Key Country Dynamics
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. Reimbursement Scenario
    • 7.3.2.5. Competitive Scenario
  • 7.3.3. Germany
    • 7.3.3.1. Germany Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.3.3.2. Key Country Dynamics
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Reimbursement Scenario
    • 7.3.3.5. Competitive Scenario
  • 7.3.4. Spain
    • 7.3.4.1. Spain Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.3.4.2. Key Country Dynamics
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Reimbursement Scenario
    • 7.3.4.5. Competitive Scenario
  • 7.3.5. France
    • 7.3.5.1. France Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.3.5.2. Key Country Dynamics
    • 7.3.5.3. Regulatory Framework
    • 7.3.5.4. Reimbursement Scenario
    • 7.3.5.5. Competitive Scenario
  • 7.3.6. Italy
    • 7.3.6.1. Italy Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.3.6.2. Key Country Dynamics
    • 7.3.6.3. Regulatory Framework
    • 7.3.6.4. Reimbursement Scenario
    • 7.3.6.5. Competitive Scenario
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.3.7.2. Key Country Dynamics
    • 7.3.7.3. Regulatory Framework
    • 7.3.7.4. Reimbursement Scenario
    • 7.3.7.5. Competitive Scenario
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.3.8.2. Key Country Dynamics
    • 7.3.8.3. Regulatory Framework
    • 7.3.8.4. Reimbursement Scenario
    • 7.3.8.5. Competitive Scenario
  • 7.3.9. Norway
    • 7.3.9.1. Norway Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.3.9.2. Key Country Dynamics
    • 7.3.9.3. Regulatory Framework
    • 7.3.9.4. Reimbursement Scenario
    • 7.3.9.5. Competitive Scenario
• 7.4. Asia Pacific
  • 7.4.1. Asia-Pacific Anatomic Pathology Market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.4.2.2. Key Country Dynamics
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Scenario
    • 7.4.2.5. Competitive Scenario
  • 7.4.3. China
    • 7.4.3.1. China Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.4.3.2. Key Country Dynamics
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Scenario
    • 7.4.3.5. Competitive Scenario
  • 7.4.4. India
    • 7.4.4.1. India Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.4.4.2. Key Country Dynamics
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Scenario
    • 7.4.4.5. Competitive Scenario
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.4.5.2. Key Country Dynamics
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Reimbursement Scenario
    • 7.4.5.5. Competitive Scenario
  • 7.4.6. Thailand
    • 7.4.6.1. Thailand Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.4.6.2. Key Country Dynamics
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Reimbursement Scenario
    • 7.4.6.5. Competitive Scenario
  • 7.4.7. Australia
    • 7.4.7.1. Australia Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.4.7.2. Key Country Dynamics
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Reimbursement Scenario
    • 7.4.7.5. Competitive Scenario
• 7.5. Latin America
  • 7.5.1. Latin America Anatomic Pathology Market, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.5.2.2. Key Country Dynamics
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Scenario
    • 7.5.2.5. Competitive Scenario
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.5.3.2. Key Country Dynamics
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Scenario
    • 7.5.3.5. Competitive Scenario
• 7.6. MEA
  • 7.6.1. MEA Anatomic Pathology Market, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.6.2.2. Key Country Dynamics
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Scenario
    • 7.6.2.5. Competitive Scenario
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.6.3.2. Key Country Dynamics
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Scenario
    • 7.6.3.5. Competitive Scenario
  • 7.6.4. UAE
    • 7.6.4.1. UAE Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.6.4.2. Key Country Dynamics
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Scenario
    • 7.6.4.5. Competitive Scenario
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Anatomic Pathology Market, 2021 - 2033 (USD Million)
    • 7.6.5.2. Key Country Dynamics
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Scenario
    • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
  • 8.2.1. New Product Launch
  • 8.2.2. Partnerships
  • 8.2.3. Acquisition
  • 8.2.4. Collaboration
  • 8.2.5. Funding
• 8.3. Key Company Market Share Analysis, 2024
• 8.4. Company Heat Map Analysis
• 8.5. Company Profiles
  • 8.5.1. Danaher
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. PHC Holdings Corporation
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Quest Diagnostics Incorporated
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Laboratory Corporation of America Holdings
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. F. Hoffmann-La Roche AG
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Agilent Technologies, Inc.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Sakura Finetek USA, Inc.
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. NeoGenomics Laboratories, Inc.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. BioGenex
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Bio SB
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives

관련자료